Page 2 - Partial Response News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Partial response. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Partial Response Today - Breaking & Trending Today

J INTS BIO, AACR 2024 - 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, showing Clinical Benefits in the Ongoing Phase 1 Study

/PRNewswire/ J INTS BIO announced the results of its ongoing Phase 1 clinical study of JIN-A02, a 4th generation EGFR-TKI for NSCLC treatment, at the 8th. ....

United States , Soult Ukpyolsi , South Korea , San Diego , American Cancer Research Society , Cancer Research Society , Annual Meeting , Dose Level , Partial Response , J Ints Bio , Medical Pharmaceuticals , Health Care Amp Hospitals , New Products Amp Services , Clinical Trials Amp Medical Discoveries ,

AACR 2024: PDC*line Pharma presents interim clinical results from last cohort of patients in phase I

Intermediary results of high dose PDC lung01 combined with pembrolizumab show mild safety profile, immunological activity and promising tumor response in Non-Small Cell Lung Cancer patientsCombination of high dose PDC lung01 with pembrolizumab in 19 evaluable patients resulted in objective response rate of 63.2% and. ....

Region Flamande , United States , Johan Vansteenkiste , Eric Halioua , American Association For Cancer Research , Non Small Cell Lung Cancer , American Association , Cancer Research , Annual Meeting , Low Dose , High Dose , Objective Response Rate , Progression Free Survival , Adverse Events , Partial Response , Stable Disease , Best Objective Response , Disease Control Rate , Not Reached , Prof Johan Vansteenkiste , Safety Monitoring Board , Beatrice De Vos , Plasmacytoid Dendritic Cells , Peripheral Blood Mononuclear Cells ,

AACR 2024: PDCline Pharma Presents Interim Clinical Results From Last Cohort of Patients in Phase I/II Trial with PDClung01 Cancer Vaccine

LIÈGE, Belgium & GRENOBLE, France, April 08, 2024 PDC line Pharma, a clinical-stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces the interim results from the last cohort of patients in its phase I/II clinical trial (PDC-LUNG-101, NCT03970746) with PDC lung01. ....

United States , South Korea , Region Flamande , Johan Vansteenkiste , Eric Halioua , American Association For Cancer Research , French Blood Bank , Lg Chem Life Sciences , Non Small Cell Lung Cancer , American Association , Cancer Research , Annual Meeting , Low Dose , High Dose , Objective Response Rate , Progression Free Survival , Partial Response , Stable Disease , Best Objective Response , Disease Control Rate , Not Reached , Prof Johan Vansteenkiste , Safety Monitoring Board , Beatrice De Vos , Plasmacytoid Dendritic Cells , Peripheral Blood Mononuclear Cells ,

Farmers protest: Govt wants to address all issues of farmers, says agriculture minister Arjun Munda

The farmers protest near the national capital continued despite agreeing to meet central government representatives again on Sunday. Agriculture minister Arjun Munda emphasized the government s desire for a peaceful resolution and prompt conclusion of talks. Talks between farmer union leaders and ministers Piyush Goyal, Nityanand Rai, and Munda in Chandigarh on Friday failed to reach an agreement after a five-hour meeting. ....

Piyush Goyal , Arjun Munda , Harpal Singh Cheema , Bhagwant Mann , Nityanand Rai , Sarwan Singh Pandher , Mahatma Gandhi State Institute , Public Administration , Samyukta Kisan Morcha , Kisan Mazdoor Morcha , Delhi Chalo , Partial Response , Bharat Bandh , Farmers Protest , Minimum Support Price , Agriculture Minister , Central Government ,

Switching to Second Line Treatment in Chronic GVHD

The panel examines the transition from systemic steroids to second-line therapies in chronic GVHD, explore standardized clinical trial definitions and real-world challenges in treating chronic GVHD. ....

United States , Dana Farber Cancer Institute , Hannah Choe , Corey Cutler , Bin Chen , Mitchell Horwitz , Ohio State University , Marrow Transplant Program At Duke University , Professor Of Medicine At Harvard Medical School , Cell Therapy Program At Massachusetts , Cell Therapy Program , Massachusetts General Hospital , Harvard Medical School , Stem Cell Transplant Program , Adult Blood , Marrow Transplant Program , Duke University , Assistant Professor , Ohio State , Yi Bin Chen , Chronic Graft Versus Host Disease , Steroid Refractory Disease , Partial Response To Steroid , Time To Switch , Deep Sclerotic Disease , Partial Response ,